Acesso livre
Acesso livre

Covid-19 (Temas de Saúde Pública)

Estudo randomizado | Vacinação em dose única contra o HPV se mostrou efetiva entre mulheres jovens na África.

14 Abr, 2022 | 17:07h

Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women – NEJM Evidence

Comunicado de imprensa:

Study boosts support for single-dose HPV vaccine regimen – University of Washington

One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer – World Health Organization

Conteúdo relacionado: Three-year follow-up of 2-dose versus 3-dose HPV vaccine

 

Comentário no Twitter (fio – clique para saber mais)

 

Mais dados sugerem que a variante Ômicron causa doença mais leve em comparação à variante Delta.

14 Abr, 2022 | 16:51h

Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study – The Lancet

Comentário: Covid-19: Symptomatic infection with omicron variant is milder and shorter than with delta, study reports – The BMJ

Conteúdos relacionados:

Another study suggests a lower risk of hospitalization and death from infection with SARS-CoV-2 Omicron variant vs. Delta.

Perspective: Challenges in inferring intrinsic severity of the SARS-CoV-2 Omicron variant.

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa.

Cohort Study: Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US.

[Preprint] SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.

[Preprint] Study showed reduced clinical severity of Covid-19 patients admitted to hospitals in Gauteng, South Africa, during the Omicron-dominant fourth wave – “any combination of a less-virulent virus, comorbidities, high immunity from prior infection(s) or vaccination may be important contributors to this clinical presentation”.

Early data from South Africa hints Omicron variant may cause less severe Covid, but more research is needed.

Too early to tell, but preliminary information from doctors in South Africa suggests the new Covid variant Omicron may be associated with less severe disease.

Análise estatística | Estimativa global, regional e nacional de infecções diárias e cumulativas por SARS-CoV-2 até 14/11/2021.

12 Abr, 2022 | 12:48h

Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis – The Lancet

Invited Commentary: How to interpret the total number of SARS-CoV-2 infections – The Lancet

 

Comentário no Twitter (fio – clique para saber mais)

 

Cuidado intensivo das infecções respiratórias agudas graves (adaptação para COVID-19, atualização 2022).

12 Abr, 2022 | 12:40h

Clinical care of severe acute respiratory infections – Tool kit – World Health Organization

 

Comentário no Twitter (fio – clique para saber mais)

 

Estudo de caso-controle e teste negativo | Vacina CoronaVac mostrou-se efetiva em evitar COVID-19 grave e sintomática em gestantes no Brasil.

12 Abr, 2022 | 12:37h

CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study – BMC Medicine

Opinião | Por que demorou 2 anos para a OMS dizer que a COVID é transmitida pelo ar.

11 Abr, 2022 | 12:55h

Why the WHO took two years to say COVID is airborne – Nature

COVID-19: diretriz conjunta do ECDC e EMA sobre a 4ª dose de vacinas de mRNA.

8 Abr, 2022 | 21:56h

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Conteúdos relacionados:

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter (fio – clique para saber mais)

 

Perspectiva | Um roteiro equitativo para acabar com a pandemia de COVID-19.

8 Abr, 2022 | 21:43h

An equitable roadmap for ending the COVID-19 pandemic – Nature Medicine

 

Comentário no Twitter

 

Estudo observacional sugere que a 4ª dose da vacina da Pfizer forneceu proteção adicional contra doença grave em pacientes com 60 anos de idade ou mais durante a onda da variante Ômicron em Israel.

8 Abr, 2022 | 21:11h

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel – New England Journal of Medicine

Comentário: Mixed Bag for Fourth Dose of Pfizer Vaccine vs Omicron— Real-world data show less infection and severity, but long-term benefit less clear – MedPage Today (necessário cadastro gratuito)

Conteúdos relacionados:

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter

 

Estudo de coorte retrospectiva | Queda na efetividade das vacinas Pfizer e CoronaVac contra COVID-19 na Malásia.

8 Abr, 2022 | 21:08h

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study – International Journal of Infectious Diseases

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.